A Phase 1/2 interventional study of Human T Lymphoid Progenitor (HTLP) injection in Hematologic Malignancy, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 5 sites in France. Open to participants aged 18 Years to 66 Years. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Hematologic Neoplasms by Assistance Publique - Hôpitaux de Paris — 6 open to participants now, 6 under way, 1 of them phase 3. Hematologic Neoplasms · Assistance Publique - Hôpitaux de Paris.
Among the 16 studies in Hematologic Neoplasms by Assistance Publique - Hôpitaux de Paris, this one is one of 2 that started in 2022, is one of 4 in phase 1/2, and was the 10th registered.
1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.
Browse Hematologic Neoplasms studies →6 of the 16 studies in Hematologic Neoplasms by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 70+
Assistance Publique - Hôpitaux de Paris
Ages 18+
By country, each count listing its studies:
Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.
This study: 18 Years to 66 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 46 across 1,047 interventional studies indexed under Hematologic Neoplasms.
Median enrollment 51 across the 9 interventional studies, 500 across the 7 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
3 of the studies in Hematologic Neoplasms by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06350994Assistance Publique - Hôpitaux de ParisEarly Assessment of Cardiac Function After Treatment With CAR-T Cells | 2026-12 |
| NCT04707300Assistance Publique - Hôpitaux de ParisStudy Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO) | 2027-06 |
| NCT02884375Assistance Publique - Hôpitaux de ParisElderly CAncer Patient | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies in Hematologic Neoplasms by Assistance Publique - Hôpitaux de Paris, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-labelled and non-controlled Phase I/II clinical trial, evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB) transplantation in adult patients with hematologic malignancies. The dose limiting toxicity of HTLP injection will be evaluated using a model-based design.
Allogeneic bone marrow transplantation (AlloSCT) is the treatment of choice for high- risk acute myeloid leukemias in complete first remission after induction therapy and other high-risk hematological malignancies. Umbilical cord blood grafts are frequently used for patients lacking an HLA- matched family donor (Matched-sibling donor, MSD) as well as in the absence of an appropriate unrelated donor (10/10 MUD). As any HSCT, UCB transplantations are associated with the risk of acute and chronic GVHD, post- transplant immunodeficiency with increased risk of infections as well as relapse. Especially the risk of infection and therefore non- relapse mortality (NRM) or transplant- related mortality (TRM) is significantly higher in UCB transplantations as compared to MSD or 10/10 MUD transplantations. All of these risks have been linked to a significant delay in immune reconstitution including various immune cell populations like CD4 and CD8 T cells, Treg, NK, iNKT, pDC and others.
The investigators therefore make the hypothesis that if T-cell-mediated immunity was rapidly generated after a partially HLA-compatible UCB transplantation will reduce the risk of infection and to prevent relapse without increasing the risk of GVHD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
AND
* For the UCB taken into HTLP culture, the CD34+ content does not need to meet the above cellularity criteria, as expansion during HTLP culture has been proven to ensure the appropriate number of CD7+ needed for each dose.
The non- cultured UCB will be chosen to have a higher CD34+ cell content in order to enable long- term hematopoietic engraftment
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HTLP cellular product obtained after 7 days of culture of immune-selected CB
Drug: Human T Lymphoid Progenitor (HTLP) injection
The HTLP cell suspension will be injected intravenously at the time of UCB HSCT on D0
Cumulative incidence of grade III-IV graft-versus-host disease (GvHD)
according to Glucksberg grading system, to define toxicity
Time frame: Within 100 Days following HSCT
CD4 + T cells analysis
Efficacy defined by the presence of \>50/μl CD4+ CD3+ TCRαβ+ T cells at 2 consecutive measures \< within 4 months post HSCT.
Time frame: Within 100 days following HSCT
Time to hematologic engraftment
ANC \> 0.5G/L and platelets \> 20G/L on 3 consecutive days
Time frame: Up to 24 months post-transplantation
Last transfusion of platelets and red blood cell
Time frame: During the follow-up
Absolute numbers of neutrophils
Time frame: Month 1, 2, 3, 6 and 12 post -transplantation
Time course of T cell immune reconstitution
by immunophenotyping (flow cytometry analysis) - with a focus on time needed to exceed a count of 100 naive CD4+ and \>100 total CD8+ cells per μL
Time frame: Month 1, 2, 3, 6 and 12 post -transplantation
Immune phenotype (flow-cytometry analysis) of the different TCRαβ+ cell subpopulations
TCD4 naive/memory population (CD31+CD45RA+/CD4+, CD45RO/CD4+; CD31+CD4+); TCD8 naive/memory population (CD45RA+CCR7+/CD8+, CD45RA-CCR7+/ CD8+, CD45RA- CCR7+/ CD8+, CD45RA-CCR7-/CD8+) , CD8 effector memory RA+ (TEMRA) (CD45RA+CCR7- /CD8+ ); Regulatory T cells (CD4+CD25+CD127lowCD25+). • Analysis of CD3, CD4, CD8 numbers will be performed if total lymphocytes ≥ 500/μL and analysis of T cell subpopulations if CD3+ cells ≥ 1000/μL
Time frame: Month 1, 2, 3, 6 and 12 post -transplantation
B-cell reconstitution
(B CD19 naive/memory population (CD27-IgD+/CD19+, CD27+IgD+/CD19+, CD27+IgD-/CD19 and Ig levels) at 1, 2, 3, 6 and 12 months post HSCT with focus on time needed for cessation of intravenously IgG replacement therapy
Time frame: Month 1, 2, 3, 6 and 12 post -transplantation
Reconstitution of the NK cell
compartment (CD16+CD56+)
Time frame: Month 1, 2, 3, 6 and 12 post -transplantation
Assessment of engraftment of each UCB unit over time by hematological monitoring and chimerism analysis
at 1, 2, 3, 6 and 12 months following HSCT and between M1 and M2 post-transplantation if necessary according to the result of the chimerism at M1 on neutrophils, T, B, NK, pDC and macrophages. • The chimerism is studied on whole blood and on mononuclear cells (i.e. cells reconditioning after Ficoll) until the total number of lymphocyte is ≥ 100/μL. When lymphocyte count is ≥ 100/μL, the chimerism will be analysed on immunoselected cell populations (CD15+/CD3+/NK, CD19+)
Time frame: at 1, 2, 3, 6 and 12 months following HSCT.
Graft failure/rejection rate
detected by hematological monitoring of each UCB unit
Time frame: at 3 months following HSCT
Cumulative incidence of infections
Time frame: at 3, 6 and 12 months post- transplantation
Cumulative incidence of acute and chronic episodes of GVHD and their grade according to Glucksberg GvHD staging.
Time frame: at 3, 6, 12 and 24 months post-transplantation
Relapse rate
Time frame: 2 years
Overall survival
Time frame: 2 years
Disease-free survival
Time frame: 2 years
Progression-free survival
Time frame: 2 years
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2022 (actual). Primary completion is estimated for Jun 2027, 64 months after the start.
Of 64 phase 1/2 interventional studies under Hematologic Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 127. This study's planned 64 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →